Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies (NASDAQ:NSTG) announced it will release its third quarter 2021 operating results after market close on November 9, 2021. A conference call will be held at 4:30pm ET to discuss the results and provide a business update. Interested parties should register in advance for the call at this link. A replay will be available from November 9, 2021 at 7:30pm ET through November 16, 2021.
NanoString is known for its nCounter Analysis System used for gene and protein profiling.
NanoString Technologies, Inc. (NASDAQ:NSTG) will webcast a presentation at the Baird 2021 Global Healthcare Conference on September 14, 2021, at 5:30 PM ET. CEO Brad Gray will lead the presentation, which can be accessed live from the investor section of their website. A replay will be available an hour after the event and archived for 60 days. NanoString is known for its innovative life science tools, including the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, which facilitate advanced research in gene and protein profiling.
NanoString Technologies (NASDAQ:NSTG) has announced that CEO Brad Gray will present at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 2:45 PM ET. The live presentation will be accessible via webcast on the company's investor website. A replay will be available one hour post-presentation, archived for 60 days. NanoString is a leader in life science tools, with products like the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, used for advanced genomic profiling in research.
NanoString Technologies (NASDAQ: NSTG) announced the publication of a peer-reviewed study in the journal Cell, showcasing the use of its GeoMx® Digital Spatial Profiler (DSP) in colorectal cancer research. The study, led by researchers from the Broad Institute, examined interactions between tumor and immune cells in colorectal cancer samples. Using advanced techniques, the study revealed spatial transcriptional regulation crucial for understanding immune-tumor dynamics. NanoString's DSP aids in high-throughput RNA and protein profiling, with over 60 publications validating its applications in research.
NanoString Technologies (NASDAQ:NSTG) reported Q2 2021 financial results, showcasing significant growth across its product lines. Product and service revenue increased by 59% to $33.6 million, driven by a 115% rise in consumables revenue. Instrument sales reached $11.8 million, including $7.4 million from GeoMx Digital Spatial Profilers. With a robust cash position of $398 million, the company updated its 2021 revenue outlook, anticipating $143 to $147 million in total revenue. New product launches and collaborations, including with the Parker Institute for Cancer Immunotherapy, further bolster growth prospects.
NanoString Technologies, Inc. (NASDAQ:NSTG) announced that it will release its second quarter 2021 operating results after market close on August 4, 2021. Following the announcement, management will hold a conference call at 4:30 PM ET to discuss the results and provide a business update. Investors can register for the call to receive dial-in details. A replay will be available starting August 4 at 7:30 PM ET, accessible via a dedicated phone line and the company’s website. NanoString is recognized for its nCounter® Analysis System and GeoMx™ Digital Spatial Profiler, significant tools in life sciences research.
NanoString Technologies (NASDAQ: NSTG) has launched the nCounter® Stem Cell Characterization Panel aimed at enhancing the analysis and optimization of stem cell lines for novel therapeutic development. This panel addresses critical challenges in stem cell research by providing a standardized assay that evaluates stem cell viability, functionality, and pluripotency through the measurement of eight essential components of stem cell biology. The novel panel, designed with input from experts, yields results in under 24 hours and is expected to facilitate advancements in various research areas such as neurological and cardiovascular diseases.
NanoString Technologies (NASDAQ: NSTG) is collaborating with the Parker Institute for Cancer Immunotherapy (PICI) on a project to enhance CAR-T cell therapy for solid tumors. This venture aims to standardize the characterization of cell therapies, utilizing NanoString's nCounter® Analysis System and a specialized gene expression panel. By analyzing key biological characteristics of existing therapies, the collaboration seeks to improve patient outcomes. Insights from this research will be shared publicly through PICI’s Cancer Data and Evidence Library (CANDEL) to benefit the broader scientific community.
NanoString Technologies (NASDAQ:NSTG) has announced that its management will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 PM ET. The presentation can be accessed via a live webcast on the company's website, with a replay available after one hour and archived for 60 days. NanoString is a prominent provider of life science tools, known for its nCounter® Analysis System, used extensively in research with over 4,300 citations. Their GeoMx® Digital Spatial Profiler allows for advanced spatial profiling of RNA and protein in various sample types.
NanoString Technologies, a leader in life science tools, will present at the UBS Global Healthcare Conference on May 25, 2021, at 1:00 PM ET. CEO Brad Gray will deliver the presentation, with a live webcast accessible through the company's investor website. The event will also have a replay available for up to 60 days after the live session. Known for its nCounter Analysis System and GeoMx Digital Spatial Profiler, NanoString facilitates groundbreaking research in biomarker discovery and validation. For further details, visit www.nanostring.com.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
